"brentuximab vedotin; relapse; Hodgkin lymphoma"@en . "L\u00E9\u010Dba a progn\u00F3za pacient\u016F s relabovan\u00FDm nebo refraktern\u00EDm Hodgkinov\u00FDm lymfomem nevhodn\u00FDch k transplantaci kmenov\u00FDch bun\u011Bk"@cs . . "This article retrospectively evaluates survival and prognosis of patients with relapsed/refractory HL who were not suitable for high-dose chemotherapy and ASCT. New drugs and their efficacy in this indication are also disscussed. Patients and Methods: A total of 17 patients treated with at least three lines of standard chemotherapy \u00B1 radiotherapy were analysed. High-dose chemotherapy and ASCT was not indicated due to advanced age (seven patients), chemorefractory disease (seven patients), cardiotoxicity (two patients) and insufficient stem cell collection of CD34+ cells (one patient). Results: Median follow-up of the whole group after establishing the diagnosis was 3.48 years. Overall response to the second-line treatment was achieved in eight patients (47.0%). Four patients (23,5%) were classified as primary refractory after the first-line treatment and three more chemorefractory patients (17,6%) were detected after the second-line treatment. Out of 17 patients four are still alive (23,5%) in remission and 13 have died (eight due to HL progressions, four due to toxicity of the treatment and one patient with unknown cause of death). The estimated 5-year overall survival from the time of initial diagnosis was 46.3% and 30.8% when counted from the diagnosis of the first relapse. The estimated 5-year overall survival of four primary chemorefractory patients was significantly worse when compared to the group of 13 relapsed patients: 0 vs. 60.6%, p < 0,001. Conclusion: Prognosis of relapsed/refractory HL patients ineligible for ASCT and treated with several lines of standard chemotherapy \u00B1 radiotherapy is poor. Brentuximab vedotin is indicated in primary refractory patients in the second-line settings and in other relapsed patients in the third-line treatment. This strategy would help to increase the number of remissions, hence achieving a higher survival rate."@en . "V\u00FDchodiska: Relapsy po l\u00E9\u010Db\u011B Hodgkinova lymfomu (HL) se vyskytuj\u00ED u 20\u2013 30 % pacient\u016F. U relabovan\u00FDch/ refraktern\u00EDch pacient\u016F s HL, kte\u0159\u00ED nejsou vhodn\u00ED k autologn\u00ED transplantaci kmenov\u00FDch bun\u011Bk (autologous stem cell transplantation \u2013 ASCT), nen\u00ED ur\u010Dena standardn\u00ED strategie l\u00E9\u010Dby. V \u010Dl\u00E1nku je retrospektivn\u011B hodnoceno p\u0159e\u017Eit\u00ED a progn\u00F3za pacient\u016F s relabovan\u00FDm/ refraktern\u00EDm HL, kte\u0159\u00ED jsou nevhodn\u00ED k vysokod\u00E1vkovan\u00E9 chemoterapii s ASCT. V diskuzi je uveden p\u0159ehled nov\u00FDch l\u00E9k\u016F pou\u017E\u00EDvan\u00FDch v t\u00E9to indikaci. Pacienti a metody: Do anal\u00FDzy bylo za\u0159azeno 17 pacient\u016F, kte\u0159\u00ED byli l\u00E9\u010Deni minim\u00E1ln\u011B t\u0159emi liniemi standardn\u00ED chemoterapie \u00B1 radioterapie. Vysokod\u00E1vkovan\u00E1 chemoterapie s ASCT nebyla indikov\u00E1na ve 2. a dal\u0161\u00ED linii l\u00E9\u010Dby z d\u016Fvodu vysok\u00E9ho v\u011Bku (sedm pacient\u016F), refrakternosti HL (sedm pacient\u016F), kardiotoxicity (dva pacienti) a pro nedostate\u010Dn\u00FD \u0161t\u011Bp kmenov\u00FDch bun\u011Bk (jeden pacient). V\u00FDsledky: Medi\u00E1n sledov\u00E1n\u00ED cel\u00E9 skupiny pacient\u016F od dia\u00ADgn\u00F3zy byl 3,48 roku. Celkov\u00E1 odpov\u011B\u010F na 2. linii l\u00E9\u010Dby byla dosa\u017Eena u osmi pacient\u016F (47,0 %). Po 1. linii l\u00E9\u010Dby byli \u010Dty\u0159i pacienti (23,5 %) prim\u00E1rn\u011B refraktern\u00ED a po 2. linii l\u00E9\u010Dby stoupl po\u010Det refraktern\u00EDch p\u0159\u00EDpad\u016F o t\u0159i pacienty (17,6 %). Ze 17 pacient\u016F \u017Eij\u00ED \u010Dty\u0159i v remisi (23,5 %) a 13 zem\u0159elo (osm na progresi HL, \u010Dty\u0159i na toxicitu a u jednoho pacienta je p\u0159\u00ED\u010Dina \u00FAmrt\u00ED nezn\u00E1m\u00E1). P\u011Btilet\u00E9 celkov\u00E9 p\u0159e\u017Eit\u00ED cel\u00E9 skupiny od dia\u00ADgn\u00F3zy bylo 46,3 % a od dia\u00ADgn\u00F3zy prvn\u00EDho relapsu 30,8 %. P\u011Btilet\u00E9 celkov\u00E9 p\u0159e\u017Eit\u00ED u \u010Dty\u0159 prim\u00E1rn\u011B refraktern\u00EDch pacient\u016F bylo v\u00FDznamn\u011B hor\u0161\u00ED ve srovn\u00E1n\u00ED se skupinou 13 relabovan\u00FDch pacient\u016F: 0 vs 60,6 %, p < 0,001. Z\u00E1v\u011Br: Progn\u00F3za relabovan\u00FDch/ refraktern\u00EDch pacient\u016F s HL nevhodn\u00FDch k ASCT, kte\u0159\u00ED byli opakovan\u011B l\u00E9\u010Deni standardn\u00ED chemoterapi\u00ED \u00B1 radioterapi\u00ED, je \u0161patn\u00E1. U prim\u00E1rn\u011B refraktern\u00EDch pacient\u016F je indikov\u00E1no za\u0159azen\u00ED brentuximab vedotinu do 2. linie l\u00E9\u010Dby a u ostatn\u00EDch relabovan\u00FDch pacient\u016F do 3. linie l\u00E9\u010Dby. Tato strategie pom\u016F\u017Ee zv\u00FD\u0161it pod\u00EDl remis\u00ED s c\u00EDlem prodlou\u017Een\u00ED celkov\u00E9ho p\u0159e\u017Eit\u00ED."@cs . "Markov\u00E1, Jana" . "L\u00E9\u010Dba a progn\u00F3za pacient\u016F s relabovan\u00FDm nebo refraktern\u00EDm Hodgkinov\u00FDm lymfomem nevhodn\u00FDch k transplantaci kmenov\u00FDch bun\u011Bk" . "25859" . . "RIV/00216208:11120/14:43909207!RIV15-MSM-11120___" . "L\u00E9\u010Dba a progn\u00F3za pacient\u016F s relabovan\u00FDm nebo refraktern\u00EDm Hodgkinov\u00FDm lymfomem nevhodn\u00FDch k transplantaci kmenov\u00FDch bun\u011Bk"@cs . "0862-495X" . . . . "RIV/00216208:11120/14:43909207" . "5"^^ . "CZ - \u010Cesk\u00E1 republika" . "M\u00F3cikov\u00E1, Heidi" . . "8"^^ . . "10.14735/amko2014424" . . "Treatment and prognosis of relapsed or refractory Hodgkin lymphoma patients ineligible for stem cell transplantation"@en . "Klinick\u00E1 onkologie" . . . "I" . . "[5D0F8D98AA13]" . . . "6" . "L\u00E9\u010Dba a progn\u00F3za pacient\u016F s relabovan\u00FDm nebo refraktern\u00EDm Hodgkinov\u00FDm lymfomem nevhodn\u00FDch k transplantaci kmenov\u00FDch bun\u011Bk" . "2"^^ . . "11120" . "27" . . "V\u00FDchodiska: Relapsy po l\u00E9\u010Db\u011B Hodgkinova lymfomu (HL) se vyskytuj\u00ED u 20\u2013 30 % pacient\u016F. U relabovan\u00FDch/ refraktern\u00EDch pacient\u016F s HL, kte\u0159\u00ED nejsou vhodn\u00ED k autologn\u00ED transplantaci kmenov\u00FDch bun\u011Bk (autologous stem cell transplantation \u2013 ASCT), nen\u00ED ur\u010Dena standardn\u00ED strategie l\u00E9\u010Dby. V \u010Dl\u00E1nku je retrospektivn\u011B hodnoceno p\u0159e\u017Eit\u00ED a progn\u00F3za pacient\u016F s relabovan\u00FDm/ refraktern\u00EDm HL, kte\u0159\u00ED jsou nevhodn\u00ED k vysokod\u00E1vkovan\u00E9 chemoterapii s ASCT. V diskuzi je uveden p\u0159ehled nov\u00FDch l\u00E9k\u016F pou\u017E\u00EDvan\u00FDch v t\u00E9to indikaci. Pacienti a metody: Do anal\u00FDzy bylo za\u0159azeno 17 pacient\u016F, kte\u0159\u00ED byli l\u00E9\u010Deni minim\u00E1ln\u011B t\u0159emi liniemi standardn\u00ED chemoterapie \u00B1 radioterapie. Vysokod\u00E1vkovan\u00E1 chemoterapie s ASCT nebyla indikov\u00E1na ve 2. a dal\u0161\u00ED linii l\u00E9\u010Dby z d\u016Fvodu vysok\u00E9ho v\u011Bku (sedm pacient\u016F), refrakternosti HL (sedm pacient\u016F), kardiotoxicity (dva pacienti) a pro nedostate\u010Dn\u00FD \u0161t\u011Bp kmenov\u00FDch bun\u011Bk (jeden pacient). V\u00FDsledky: Medi\u00E1n sledov\u00E1n\u00ED cel\u00E9 skupiny pacient\u016F od dia\u00ADgn\u00F3zy byl 3,48 roku. Celkov\u00E1 odpov\u011B\u010F na 2. linii l\u00E9\u010Dby byla dosa\u017Eena u osmi pacient\u016F (47,0 %). Po 1. linii l\u00E9\u010Dby byli \u010Dty\u0159i pacienti (23,5 %) prim\u00E1rn\u011B refraktern\u00ED a po 2. linii l\u00E9\u010Dby stoupl po\u010Det refraktern\u00EDch p\u0159\u00EDpad\u016F o t\u0159i pacienty (17,6 %). Ze 17 pacient\u016F \u017Eij\u00ED \u010Dty\u0159i v remisi (23,5 %) a 13 zem\u0159elo (osm na progresi HL, \u010Dty\u0159i na toxicitu a u jednoho pacienta je p\u0159\u00ED\u010Dina \u00FAmrt\u00ED nezn\u00E1m\u00E1). P\u011Btilet\u00E9 celkov\u00E9 p\u0159e\u017Eit\u00ED cel\u00E9 skupiny od dia\u00ADgn\u00F3zy bylo 46,3 % a od dia\u00ADgn\u00F3zy prvn\u00EDho relapsu 30,8 %. P\u011Btilet\u00E9 celkov\u00E9 p\u0159e\u017Eit\u00ED u \u010Dty\u0159 prim\u00E1rn\u011B refraktern\u00EDch pacient\u016F bylo v\u00FDznamn\u011B hor\u0161\u00ED ve srovn\u00E1n\u00ED se skupinou 13 relabovan\u00FDch pacient\u016F: 0 vs 60,6 %, p < 0,001. Z\u00E1v\u011Br: Progn\u00F3za relabovan\u00FDch/ refraktern\u00EDch pacient\u016F s HL nevhodn\u00FDch k ASCT, kte\u0159\u00ED byli opakovan\u011B l\u00E9\u010Deni standardn\u00ED chemoterapi\u00ED \u00B1 radioterapi\u00ED, je \u0161patn\u00E1. U prim\u00E1rn\u011B refraktern\u00EDch pacient\u016F je indikov\u00E1no za\u0159azen\u00ED brentuximab vedotinu do 2. linie l\u00E9\u010Dby a u ostatn\u00EDch relabovan\u00FDch pacient\u016F do 3. linie l\u00E9\u010Dby. Tato strategie pom\u016F\u017Ee zv\u00FD\u0161it pod\u00EDl remis\u00ED s c\u00EDlem prodlou\u017Een\u00ED celkov\u00E9ho p\u0159e\u017Eit\u00ED." . "Treatment and prognosis of relapsed or refractory Hodgkin lymphoma patients ineligible for stem cell transplantation"@en .